Newsroom | 12764 results

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the award of inducement grants. On August 5, 2026, as an inducement material to acceptance of employment with CareDx, 35 new employees were awarded restricted stock units (RSUs) for an aggregate of 97,090 shares of common stock. With respect to 34 of the new employees, an aggregate of 93,090 of the RSUs will vest o...

LOS ANGELES--(BUSINESS WIRE)--OneLegacy, the organ, eye, and tissue procurement organization serving seven counties in Southern California since 1977, set a new monthly record for July, enabling the transplantation of 210 lifesaving organs, thanks to the generosity of 71 donors and their families, and the expert coordination of dedicated medical teams. This milestone reflects the strength of collaboration across Southern California's donation and transplantation community. Working around the cl...

CAESAREA, Israel--(BUSINESS WIRE)--ForSight Robotics, a global pioneer in robotic eye surgery, today announced a significant milestone in the clinical evolution of ophthalmic robotics, demonstrating that fully robotic-assisted cataract surgery can be successfully integrated into the standard clinical workflow of the world's most commonly performed surgical procedure. Building on the Company's historic first-in-human achievement announced earlier this year, ForSight Robotics has successfully com...

HOUSTON--(BUSINESS WIRE)--IPS HEART, Inc., a biopharmaceutical company pioneering induced pluripotent stem cell (iPSC)-derived cell replacement therapies, announced that the FDA has granted Rare Pediatric Drug Designation for ISX9-CPC, for the treatment of cardiomyopathies associated with dystrophinopathies. Redefining the Therapeutic Paradigm: Generating New Human Muscle Duchenne muscular dystrophy (DMD) leads to progressive skeletal muscle loss, severe cardiac fibrosis, and premature death fr...

RICHMOND, Va.--(BUSINESS WIRE)--McKesson Medical Surgical unveils meaning and vision of new name, branding, as part of planned separation; expects to transition to new name in 2027....

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2026. Second Quarter Highlights and Outlook (Unaudited) Revenue of $67.5 million, up 31.7% from Q2 2025, and sequential growth of 12.8% from Q1 2026 $24.7 million of sales in the United States, up 26% from Q1 2...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced changes to its Board of Directors. At the request of Bausch Health Companies Inc. (“Bausch Health”), which has held a majority ownership position in Bausch + Lomb since its initial public offering in 2022 and currently owns, directly or indirectly through its wholly owned subsidiaries, approximately 87% of the c...

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 30, 2026, to shareholders of record at the close of business on August 14, 2026. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to bec...

WATERTOWN, Mass.--(BUSINESS WIRE)--LifeMine Therapeutics Inc., a clinical-stage biopharmaceutical company pioneering Top-Down Drug Discovery™, which leverages digital genomic search technology from fungi to source next-generation precision medicines, today announced $263 million in financing to accelerate the clinical development of the company’s lead program, LIFE-001, and advance its pipeline of novel transplantation and immunology therapies. LIFE-001 is a structurally and mechanistically nov...

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended June 30, 2026. Second quarter 2026 continuing operations financial summary1 Revenue from continuing operations of $570.3 million, up 28.9% compared to the prior year period, and up 4.7% on a pro forma adjusted constant currency basis1,2 GAAP diluted EPS from continuing operations of $0.96, compared to $1.54 in the prior year period Adjusted diluted EPS fr...